Beam Therapeutics Expects Risto-cel BLA Filing as Early as Year-End 2026

Beam expects to submit a biologics license application for investigational risto-cel as early as year-end 2026. Updated BEACON Phase 1/2 data, including initial patient-reported outcomes, are scheduled for presentation at ASH on December 12, 2026.